MX2020014097A - Lipidos novedosos. - Google Patents

Lipidos novedosos.

Info

Publication number
MX2020014097A
MX2020014097A MX2020014097A MX2020014097A MX2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A
Authority
MX
Mexico
Prior art keywords
novel lipids
lipids
novel
present
invention includes
Prior art date
Application number
MX2020014097A
Other languages
English (en)
Inventor
Daniel Emil Levy
Annie Bouchard
James Mcchesney
Saravanan Kappusamy
John Kallikat Augustine
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of MX2020014097A publication Critical patent/MX2020014097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente invención incluye un compuesto que tiene la siguiente fórmula estructural: (ver Fórmula).
MX2020014097A 2018-06-26 2019-06-26 Lipidos novedosos. MX2020014097A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690196P 2018-06-26 2018-06-26
PCT/US2019/039162 WO2020006033A1 (en) 2018-06-26 2019-06-26 Novel lipids
US16/452,858 US10975111B2 (en) 2018-06-26 2019-06-26 Cardiopathy-reducing phosphodiester lipids

Publications (1)

Publication Number Publication Date
MX2020014097A true MX2020014097A (es) 2021-04-13

Family

ID=68980509

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014097A MX2020014097A (es) 2018-06-26 2019-06-26 Lipidos novedosos.

Country Status (10)

Country Link
US (3) US10975111B2 (es)
EP (1) EP3813820A4 (es)
JP (2) JP7325840B2 (es)
KR (1) KR102627389B1 (es)
CN (1) CN112367986A (es)
AU (2) AU2019291808A1 (es)
CA (1) CA3103918C (es)
MX (1) MX2020014097A (es)
TW (1) TWI731336B (es)
WO (1) WO2020006033A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731336B (zh) 2018-06-26 2021-06-21 美商標徑製藥公司 新穎脂質
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US20240091242A1 (en) * 2021-01-29 2024-03-21 Signpath Pharma, Inc. Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokines
CN116963724A (zh) * 2021-03-03 2023-10-27 萨恩帕斯药物有限公司 用于人类恶性胸腔积液的治疗
WO2024064536A1 (en) * 2022-09-22 2024-03-28 Signpath Pharma, Inc. Cardioprotective lipid and method of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
CA2587103A1 (en) 2004-11-08 2006-05-18 Neopharm, Inc. Synthesis of cardiolipin analogues and uses thereof
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
CA2933204C (en) 2013-12-18 2020-04-28 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP3151837B1 (en) 2014-06-03 2023-03-15 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
CN105273001A (zh) * 2014-07-21 2016-01-27 南京绿叶制药有限公司 一种合成磷脂酰甘油单钠盐的方法
CN105985373A (zh) 2015-04-10 2016-10-05 江苏东南纳米材料有限公司 一种制备（r）-1,2-二脂肪酸甘油磷酯酰甘油酯的新方法
CN106188169B (zh) * 2016-07-07 2019-06-25 沈阳药科大学 一种含有唾液酸基团的脂质衍生物的合成及其在药物制剂中的应用
US20190008878A1 (en) * 2017-07-07 2019-01-10 Signpath Pharma Inc. Compositions and method for reducing cardiotoxicity
TWI731336B (zh) 2018-06-26 2021-06-21 美商標徑製藥公司 新穎脂質

Also Published As

Publication number Publication date
CA3103918A1 (en) 2020-01-02
JP7325840B2 (ja) 2023-08-15
JP2021534076A (ja) 2021-12-09
AU2019291808A1 (en) 2021-01-14
US20210198294A1 (en) 2021-07-01
CA3103918C (en) 2023-09-19
TW202019404A (zh) 2020-06-01
WO2020006033A1 (en) 2020-01-02
JP2023153882A (ja) 2023-10-18
EP3813820A4 (en) 2022-05-04
US20220056057A1 (en) 2022-02-24
US20190389888A1 (en) 2019-12-26
AU2022205275A1 (en) 2022-08-11
CN112367986A (zh) 2021-02-12
KR102627389B1 (ko) 2024-01-19
KR20210018926A (ko) 2021-02-18
US11746119B2 (en) 2023-09-05
US10975111B2 (en) 2021-04-13
TWI731336B (zh) 2021-06-21
EP3813820A1 (en) 2021-05-05
US11643424B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
ZA202102549B (en) Substituted tolyl as fungicides
MX2020014097A (es) Lipidos novedosos.
PH12018501096A1 (en) Modulators of chemokine receptors
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
AU2018258581A8 (en) RAF-degrading conjugate compounds
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
MX2018006148A (es) Inhibidores de cxcr2.
CU24435B1 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
PH12020500655A1 (en) Compounds
EA201992177A1 (ru) Композиции на основе нирапариба
AU2018293627A1 (en) New azaquinoline derivatives
MX2020010657A (es) Derivados de oxadiazolina.
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
CA185542S (en) Table
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
MX2021004386A (es) Compuestos novedosos.
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2020008689A (es) Composicion herbicida que comprende por lo menos un compuesto activo fenolico.